They found the following concordance rates for EGFR mutations: paired pulmonary primary nodules, 76 % (31/41); paired primary lung tumours and distant metastases, 86 % (30/35); paired primary lung tumours and metastatic lymph nodes, 90 % (44/49); and paired metachronous primary tumours (i.e. diagnosed at different times), 91 % (50/55). This evidence concerns the gene EGFR and neoplasm.